Reneo Pharma Q2 net loss $9.2M vs $3.7M; cash $167.3M; STRIDE study first patient dosed

OnKure Therapeutics, Inc.

2022-Q2 EPS reported -$1.40

Net loss of $9.2M ($0.43/share) for Q2 2021, compared to net loss of $3.7M ($1.82/share) in Q2 2020.
Cash, cash equivalents and short-term investments of $167.3M as of June 30, 2021.
First patient dosed in Phase 2b STRIDE trial of REN001 in primary mitochondrial myopathies (PMM); McArdle disease study enrollment completed.
R&D expenses increased to $6.3M from $2.8M; G&A expenses rose to $2.9M from $0.9M.
Anticipated milestones: McArdle results Q1 2022, LC-FAOD results H1 2022, FORWARD study results H2 2022.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.